Zenas BioPharma (ZBIO) Competitors

$18.90 -1.03 (-5.17%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$19.26 +0.36 (+1.91%)

As of 08:03 AM Eastern

ZBIO vs. LGND, CLDX, BCRX, INVA, and NVAX

Should you buy Zenas BioPharma stock or one of its competitors? MarketBeat compares Zenas BioPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zenas BioPharma include Ligand Pharmaceuticals (LGND), Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), Innoviva (INVA), and Novavax (NVAX). These companies are all part of the "biotechnology" industry.

How does Zenas BioPharma compare to Ligand Pharmaceuticals?

Ligand Pharmaceuticals (NASDAQ:LGND) and Zenas BioPharma (NASDAQ:ZBIO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

Ligand Pharmaceuticals has a net margin of 55.95% compared to Zenas BioPharma's net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 16.19% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	55.95%	16.19%	11.13%
Zenas BioPharma	N/A	-112.13%	-76.14%

Ligand Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	16.37	$124.45M	$7.37	29.71
Zenas BioPharma	$10M	108.43	-$377.74M	-$7.81	N/A

In the previous week, Ligand Pharmaceuticals had 4 more articles in the media than Zenas BioPharma. MarketBeat recorded 13 mentions for Ligand Pharmaceuticals and 9 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 1.05 beat Ligand Pharmaceuticals' score of 0.31 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zenas BioPharma	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ligand Pharmaceuticals presently has a consensus price target of $257.71, suggesting a potential upside of 17.69%. Zenas BioPharma has a consensus price target of $44.29, suggesting a potential upside of 134.32%. Given Zenas BioPharma's higher possible upside, analysts plainly believe Zenas BioPharma is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Zenas BioPharma	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 7.0% of Ligand Pharmaceuticals shares are owned by company insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Ligand Pharmaceuticals has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.61, indicating that its share price is 161% less volatile than the broader market.

Summary

Ligand Pharmaceuticals beats Zenas BioPharma on 12 of the 16 factors compared between the two stocks.

How does Zenas BioPharma compare to Celldex Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and Zenas BioPharma (NASDAQ:ZBIO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

Celldex Therapeutics' return on equity of -50.72% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-50.72%	-46.59%
Zenas BioPharma	N/A	-112.13%	-76.14%

Celldex Therapeutics has higher earnings, but lower revenue than Zenas BioPharma. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,653.90	-$258.76M	-$4.26	N/A
Zenas BioPharma	$10M	108.43	-$377.74M	-$7.81	N/A

In the previous week, Celldex Therapeutics had 6 more articles in the media than Zenas BioPharma. MarketBeat recorded 15 mentions for Celldex Therapeutics and 9 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 1.05 beat Celldex Therapeutics' score of 0.88 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Celldex Therapeutics presently has a consensus price target of $49.78, suggesting a potential upside of 53.40%. Zenas BioPharma has a consensus price target of $44.29, suggesting a potential upside of 134.32%. Given Zenas BioPharma's higher possible upside, analysts plainly believe Zenas BioPharma is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Zenas BioPharma	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44

Celldex Therapeutics has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.61, indicating that its stock price is 161% less volatile than the broader market.

Summary

Celldex Therapeutics beats Zenas BioPharma on 10 of the 14 factors compared between the two stocks.

How does Zenas BioPharma compare to BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Zenas BioPharma (NASDAQ:ZBIO) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 5.1% of BioCryst Pharmaceuticals shares are owned by insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Zenas BioPharma has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -51.71%. BioCryst Pharmaceuticals' return on equity of -76.36% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%
Zenas BioPharma	N/A	-112.13%	-76.14%

BioCryst Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84M	2.78	$263.86M	-$1.78	N/A
Zenas BioPharma	$10M	108.43	-$377.74M	-$7.81	N/A

In the previous week, BioCryst Pharmaceuticals had 4 more articles in the media than Zenas BioPharma. MarketBeat recorded 13 mentions for BioCryst Pharmaceuticals and 9 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 1.05 beat BioCryst Pharmaceuticals' score of 0.27 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zenas BioPharma	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioCryst Pharmaceuticals has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.61, suggesting that its stock price is 161% less volatile than the broader market.

BioCryst Pharmaceuticals currently has a consensus price target of $20.70, suggesting a potential upside of 116.30%. Zenas BioPharma has a consensus price target of $44.29, suggesting a potential upside of 134.32%. Given Zenas BioPharma's higher probable upside, analysts plainly believe Zenas BioPharma is more favorable than BioCryst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75
Zenas BioPharma	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44

Summary

BioCryst Pharmaceuticals beats Zenas BioPharma on 10 of the 16 factors compared between the two stocks.

How does Zenas BioPharma compare to Innoviva?

Innoviva (NASDAQ:INVA) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

99.1% of Innoviva shares are owned by institutional investors. 2.0% of Innoviva shares are owned by insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Innoviva has a net margin of 119.89% compared to Zenas BioPharma's net margin of 0.00%. Innoviva's return on equity of 33.33% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
Zenas BioPharma	N/A	-112.13%	-76.14%

Innoviva has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	4.10	$271.17M	$6.01	3.80
Zenas BioPharma	$10M	108.43	-$377.74M	-$7.81	N/A

In the previous week, Zenas BioPharma had 4 more articles in the media than Innoviva. MarketBeat recorded 9 mentions for Zenas BioPharma and 5 mentions for Innoviva. Zenas BioPharma's average media sentiment score of 1.05 beat Innoviva's score of 0.82 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Innoviva has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.61, suggesting that its stock price is 161% less volatile than the broader market.

Innoviva currently has a consensus price target of $36.20, suggesting a potential upside of 58.36%. Zenas BioPharma has a consensus price target of $44.29, suggesting a potential upside of 134.32%. Given Zenas BioPharma's higher probable upside, analysts plainly believe Zenas BioPharma is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Zenas BioPharma	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44

Summary

Innoviva beats Zenas BioPharma on 10 of the 16 factors compared between the two stocks.

How does Zenas BioPharma compare to Novavax?

Zenas BioPharma (NASDAQ:ZBIO) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

Zenas BioPharma has a net margin of 0.00% compared to Novavax's net margin of -14.73%. Novavax's return on equity of -14.82% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-112.13%	-76.14%
Novavax	-14.73%	-14.82%	1.23%

53.0% of Novavax shares are held by institutional investors. 22.0% of Zenas BioPharma shares are held by insiders. Comparatively, 1.0% of Novavax shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Novavax had 12 more articles in the media than Zenas BioPharma. MarketBeat recorded 21 mentions for Novavax and 9 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 1.05 beat Novavax's score of 0.76 indicating that Zenas BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novavax	11 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Zenas BioPharma currently has a consensus price target of $44.29, suggesting a potential upside of 134.32%. Novavax has a consensus price target of $12.13, suggesting a potential upside of 29.68%. Given Zenas BioPharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Zenas BioPharma is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10

Novavax has higher revenue and earnings than Zenas BioPharma. Novavax is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	108.43	-$377.74M	-$7.81	N/A
Novavax	$1.12B	1.37	$440.30M	-$0.58	N/A

Zenas BioPharma has a beta of -0.61, indicating that its share price is 161% less volatile than the broader market. Comparatively, Novavax has a beta of 2.37, indicating that its share price is 137% more volatile than the broader market.

Summary

Zenas BioPharma and Novavax tied by winning 8 of the 16 factors compared between the two stocks.

Get Zenas BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZBIO vs. The Competition

Export

Metric	Zenas BioPharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.14B	$3.42B	$6.34B	$12.37B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-2.23	18.47	20.66	25.63
Price / Sales	108.43	294.84	542.63	76.59
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	4.19	6.93	9.93	6.97
Net Income	-$377.74M	$24.11M	$3.55B	$333.62M
7 Day Performance	-3.77%	5.89%	1.70%	1.09%
1 Month Performance	-10.21%	-0.91%	0.49%	3.08%
1 Year Performance	94.05%	74.58%	39.41%	35.68%

Zenas BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZBIO Zenas BioPharma	3.5548 of 5 stars	$18.90 -5.2%	$44.29 +134.3%	+117.7%	$1.14B	$10M	N/A	N/A	Earnings Report Analyst Forecast
LGND Ligand Pharmaceuticals	3.7007 of 5 stars	$222.00 +0.7%	$257.71 +16.1%	+108.4%	$4.45B	$274.48M	30.12	80	Earnings Report Insider Trade
CLDX Celldex Therapeutics	2.8931 of 5 stars	$32.00 -0.9%	$48.00 +50.0%	+71.3%	$2.53B	$1.54M	N/A	150	Analyst Forecast Analyst Revision
BCRX BioCryst Pharmaceuticals	3.7596 of 5 stars	$8.80 +2.6%	$20.70 +135.2%	-2.8%	$2.18B	$874.84M	N/A	530
INVA Innoviva	4.1352 of 5 stars	$22.74 +1.0%	$36.20 +59.2%	+26.9%	$1.67B	$411.33M	3.78	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZBIO) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zenas BioPharma (ZBIO) Competitors

ZBIO vs. LGND, CLDX, BCRX, INVA, and NVAX

How does Zenas BioPharma compare to Ligand Pharmaceuticals?

Summary

How does Zenas BioPharma compare to Celldex Therapeutics?

Summary

How does Zenas BioPharma compare to BioCryst Pharmaceuticals?

Summary

How does Zenas BioPharma compare to Innoviva?

Summary

How does Zenas BioPharma compare to Novavax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZBIO vs. The Competition

Zenas BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zenas BioPharma (ZBIO) Competitors

ZBIO vs. LGND, CLDX, BCRX, INVA, and NVAX

How does Zenas BioPharma compare to Ligand Pharmaceuticals?

Is LGND or ZBIO more profitable?

Which has preferable valuation and earnings, LGND or ZBIO?

Does the media prefer LGND or ZBIO?

Do analysts prefer LGND or ZBIO?

Do insiders & institutionals hold more shares of LGND or ZBIO?

Which has more volatility & risk, LGND or ZBIO?

Summary

How does Zenas BioPharma compare to Celldex Therapeutics?

Is CLDX or ZBIO more profitable?

Which has preferable valuation and earnings, CLDX or ZBIO?

Does the media prefer CLDX or ZBIO?

Do analysts prefer CLDX or ZBIO?

Which has more risk & volatility, CLDX or ZBIO?

Summary

How does Zenas BioPharma compare to BioCryst Pharmaceuticals?

Do institutionals & insiders hold more shares of BCRX or ZBIO?

Is BCRX or ZBIO more profitable?

Which has better earnings and valuation, BCRX or ZBIO?

Does the media prefer BCRX or ZBIO?

Which has more risk & volatility, BCRX or ZBIO?

Do analysts prefer BCRX or ZBIO?

Summary

How does Zenas BioPharma compare to Innoviva?

Do institutionals & insiders hold more shares of INVA or ZBIO?

Is INVA or ZBIO more profitable?

Which has better earnings and valuation, INVA or ZBIO?

Does the media prefer INVA or ZBIO?

Which has more risk & volatility, INVA or ZBIO?

Do analysts prefer INVA or ZBIO?

Summary

How does Zenas BioPharma compare to Novavax?

Is ZBIO or NVAX more profitable?

Do insiders and institutionals hold more shares of ZBIO or NVAX?

Does the media favor ZBIO or NVAX?

Do analysts recommend ZBIO or NVAX?

Which has stronger earnings and valuation, ZBIO or NVAX?

Which has more volatility & risk, ZBIO or NVAX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZBIO vs. The Competition

Zenas BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools